ProShares Ultra NASDAQ Biotechnology
BIB
BIB
27 hedge funds and large institutions have $16.2M invested in ProShares Ultra NASDAQ Biotechnology in 2018 Q4 according to their latest regulatory filings, with 3 funds opening new positions, 4 increasing their positions, 9 reducing their positions, and 16 closing their positions.
New
Increased
Maintained
Reduced
Closed
more call options, than puts
Call options by funds: $ | Put options by funds: $
less ownership
Funds ownership: →
less funds holding
Funds holding: →
less capital invested
Capital invested by funds: $ → $
56% less repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 9
81% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 16
Holders
27
Holding in Top 10
–
Calls
$6.66M
Puts
$4.96M
Top Buyers
| 1 | +$1.97M | |
| 2 | +$1.52M | |
| 3 | +$666K | |
| 4 |
SBIA
Sheaff Brock Investment Advisors
Indianapolis,
Indiana
|
+$210K |
| 5 |
BRC
Bell Rock Capital
Rehoboth Beach,
Delaware
|
+$169K |
Top Sellers
| 1 | -$6.93M | |
| 2 | -$2.2M | |
| 3 | -$866K | |
| 4 |
TFA
Toth Financial Advisory
Leesburg,
Virginia
|
-$805K |
| 5 |
SAM
Stansberry Asset Management
Westlake,
Texas
|
-$675K |